Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
载脂蛋白 B100 脂蛋白的载脂蛋白 C3 负载与 1 型糖尿病患者的心血管疾病
基本信息
- 批准号:10370044
- 负责人:
- 金额:$ 86.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-05 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgeAntisense Oligonucleotide TherapyAntisense OligonucleotidesApolipoproteinsApolipoproteins BArterial Fatty StreakAtherosclerosisAutomobile DrivingBloodBlood PressureBody fatBody mass indexCardiovascular DiseasesCardiovascular systemClinical ResearchClinical TrialsCollaborationsComplementComplications of Diabetes MellitusCoronary ArteriosclerosisCoronary arteryDataDiabetes MellitusDiabetic mouseEndothelial CellsEpidemiologyGlucoseHepaticHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHumanHyperglycemiaHypertriglyceridemiaIDL lipoproteinsImpairmentIncidenceInflammationInsulinInsulin-Dependent Diabetes MellitusInvestigationIsotopesLDL Cholesterol LipoproteinsLesionLipidsLipolysisLipoproteinsLiverLow-Density LipoproteinsMetabolicMetabolic Clearance RateMethodsMusMyeloid CellsNormal RangeOutcomePathogenesisPathway interactionsPatientsPersonsPlasmaProductionProspective StudiesProteinsProteomicsResearch DesignRiskRisk FactorsSamplingSeriesSerumSmooth Muscle MyocytesStudy SubjectTestingTriglyceridesUniversitiesVery low density lipoproteinWashingtonWorkbasecardiovascular disorder preventioncardiovascular disorder riskcoronary artery calciumdiabeticexperimental studyfollow-upglycemic controlhigh riskinsightion mobilitylow density lipoprotein triglyceridemetabolic abnormality assessmentmouse modelnon-diabeticnovel strategiesparticleprematurepreventprospectiverisk predictionsexstable isotopetherapeutic target
项目摘要
We recently showed that serum levels of apolipoprotein C3 (APOC3) predicted incident cardiovascular disease
(CVD) in CACTI, a prospective study of subjects with type 1 diabetes mellitus (T1DM). In complementary
mechanistic studies, we found that reducing APOC3 levels with an antisense oligonucleotide (ASO) prevented
lesion progression in a mouse model of T1DM and that apolipoprotein B (APOB)-containing lipoproteins were
driving accelerated diabetic atherosclerosis. These observations are important because they strongly support
the proposal that APOC3 promotes atherosclerosis in the setting of T1DM in both humans and mice. This is
particularly important because ASOs to APOC3 are under investigation in humans, raising the possibility that it
may be possible to reduce CVD risk in T1DM patients by lowering APOC3 levels.
Our preliminary data strongly support the hypothesis that APOC3 accumulation in APOB100-containing
lipoproteins, intermediate-density lipoprotein (IDL) and LDL, makes these particles atherogenic in T1DM. To
test this hypothesis, and to lay the groundwork for a clinical trial of APOC3 ASO therapy in the prevention of
CVD in T1DM patients, we propose two specific aims.
First, we will determine whether levels of APOC3 in IDL and/or LDL predict incident CVD risk in the
Pittsburgh Epidemiology of Diabetes Complications study, a large prospective study. Our proposed study is
well powered with ~550 T1DM patients and >30% rate of incident CVD. These studies will take advantage of a
state-of-the-art method we developedtermed calibrated ion mobility analysisthat quantifies molar
concentrations of APOB100-containing lipoprotein particles in blood. Our primary analysis will be to determine
if i) IDL-APOC3 and/or ii) LDL-APOC3 predict incident CVD.
Second, we will perform detailed metabolic studies to determine how T1DM alters hepatic APOC3
production and VLDL turnover rates, and how this impacts the accumulation of APOC3 in LDL and IDL in
humans with and without T1DM. Based on our mouse studies, we hypothesize that T1DM promotes increased
levels of hepatic APOC3 production that impairs TG lipolysis, resulting in increased levels of IDL-APOC3
and/or LDL-APOC3. We will complement these analyses with comprehensive analyses of the metabolic factors
(e.g., body fat composition, liver triglycerides, hepatic sinusoidal insulin concentration) that might regulate the
concentration of APOC3 in LDL, IDL and VLDL.
Identifying patients at increased risk for CVD should provide mechanistic insights into the pathogenesis of
accelerated atherosclerosis in T1DM. Moreover, it would lay the groundwork for a clinical study of APOC3
lowering therapy in T1DM because it could target patients at high risk of CVD.
我们最近发现血清载脂蛋白C3(APOC 3)水平可预测心血管疾病的发生
(CVD)在CACTI中,1型糖尿病(T1 DM)受试者的前瞻性研究。以互补
机制研究中,我们发现用反义寡核苷酸(阿索)降低APOC 3水平可以防止
在T1 DM小鼠模型中病变进展和含载脂蛋白B(APOB)的脂蛋白被
加速糖尿病动脉粥样硬化这些观察结果很重要,因为它们强烈支持
APOC 3在人类和小鼠的T1 DM背景下促进动脉粥样硬化的提议。这是
特别重要的是,因为APOC 3的ASO正在人类中进行研究,这增加了它的可能性。
可能通过降低APOC 3水平来降低T1 DM患者的CVD风险。
我们的初步数据强烈支持这一假设,即APOC 3在含有APOB 100的细胞中的积累,
脂蛋白、中密度脂蛋白(IDL)和LDL使这些颗粒在T1 DM中致动脉粥样硬化。到
为了验证这一假设,并为APOC 3阿索治疗预防糖尿病的临床试验奠定基础,
对于T1 DM患者的CVD,我们提出了两个具体目标。
首先,我们将确定IDL和/或LDL中的APOC 3水平是否可以预测心血管事件的风险。
匹兹堡糖尿病并发症流行病学研究,大型前瞻性研究。我们建议的研究是
把握度良好,约550例T1 DM患者和>30%的CVD事件发生率。这些研究将利用一个
我们开发了一种称为校准离子迁移率分析的最先进的方法,
血液中含有APOB 100的脂蛋白颗粒的浓度。我们的主要分析将是确定
如果i)IDL-APOC 3和/或ii)LDL-APOC 3预测发生CVD。
其次,我们将进行详细的代谢研究,以确定T1 DM如何改变肝脏APOC 3
生产和VLDL周转率,以及这如何影响LDL和IDL中APOC 3的积累,
患有和不患有T1 DM的人。基于我们的小鼠研究,我们假设T1 DM促进增加
肝脏APOC 3产生水平降低,损害TG脂解,导致IDL-APOC 3水平升高
和/或LDL-APOC 3。我们将通过对代谢因素的综合分析来补充这些分析
(e.g.,体脂肪组成、肝甘油三酯、肝窦胰岛素浓度),可能调节
LDL、IDL和VLDL中的APOC 3浓度。
识别CVD风险增加的患者应该为CVD的发病机制提供机制性见解。
加速T1 DM的动脉粥样硬化。此外,这将为APOC 3的临床研究奠定基础
降低T1 DM的治疗,因为它可以针对CVD高风险患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAY W HEINECKE其他文献
JAY W HEINECKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAY W HEINECKE', 18)}}的其他基金
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
载脂蛋白 B100 脂蛋白的载脂蛋白 C3 负载与 1 型糖尿病患者的心血管疾病
- 批准号:
10546500 - 财政年份:2022
- 资助金额:
$ 86.23万 - 项目类别:
Project 4: Lipoproteins and CVD risk in diabetes
项目 4:糖尿病中的脂蛋白和 CVD 风险
- 批准号:
10642754 - 财政年份:2020
- 资助金额:
$ 86.23万 - 项目类别:
Project 4: Lipoproteins and CVD risk in diabetes
项目 4:糖尿病中的脂蛋白和 CVD 风险
- 批准号:
10450864 - 财政年份:2020
- 资助金额:
$ 86.23万 - 项目类别:
Cardioprotection by extra-small HDL particles
超小 HDL 颗粒的心脏保护作用
- 批准号:
10711262 - 财政年份:2016
- 资助金额:
$ 86.23万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 86.23万 - 项目类别:
Directed Grant